New diabetes shot tested for better blood sugar control

NCT ID NCT06849843

Summary

This study tested a new injectable medication called Efsubaglutide Alfa for people with type 2 diabetes whose blood sugar was still too high despite diet and exercise. It involved 59 participants and compared two different dosing schedules—one shot every two weeks versus one shot every week—over 12 weeks to see which was better at lowering long-term blood sugar levels (HbA1c). The main goal was to see if the less frequent injection worked as well as the weekly one.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CangZhou Hospital of Integrated TCM and Western Medicine in Hebei Province

    Cangzhou, China

  • Huzhou Central Hospital

    Huzhou, China

  • Jiangsu Province Offical Hospital

    Nanjing, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, 210008, China

  • Ningbo First Hospital

    Ningbo, China

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • The Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China

  • Wenzhou Central Hospital

    Wenzhou, China

  • Zibo Municipal Hospital

    Zibo, China

Conditions

Explore the condition pages connected to this study.